Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2022-07-12 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Alligator Bioscience AB covering the second quarter (Q2) and the first half (H1) of 2022. It includes detailed financial statements (income statement, cash flow, balance sheet data), management's discussion and analysis (CEO comments, operational updates), and performance metrics. It is not a short announcement or a certification, but a full interim report. Q2 2022
2022-07-12 English
Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
AGM Information Classification · 1% confidence The document is explicitly titled 'Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022'. It details the resolutions adopted during this meeting, including the adoption of accounts, election of board members, remuneration decisions, and authorizations regarding share issues and warrant programs. These topics are central to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (11045 chars) is substantial, confirming it is the primary report/bulletin, not just a brief announcement of publication (RPA/RNS).
2022-05-05 English
Kommuniké från årsstämma den 5 maj 2022 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled "Kommuniké från årsstämma den 5 maj 2022 i Alligator Bioscience AB" (Communication from the Annual General Meeting held on May 5, 2022, in Alligator Bioscience AB). It details the resolutions passed at the meeting, including the approval of financial statements, discharge of the board, election of directors and auditors, approval of remuneration reports, and authorization for share issues/option programs. These are the core activities and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/communication of the results, not a proxy statement (PSI) or a full regulatory filing (RNS) for a general announcement.
2022-05-05 Swedish
Alligator Bioscience AB: Delårsrapport januari–mars 2022
Regulatory Filings Classification · 1% confidence The document is a short, generic portal page from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding 'Börsinformation' (Stock Exchange Information). It does not contain specific financial results, board changes, or corporate reports, but rather serves as a landing page or a generic regulatory notification interface. Given the lack of specific content and its nature as a general regulatory portal, it falls under the fallback category for regulatory announcements.
2022-04-27 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for Alligator Bioscience AB covering the period January–March 2022. It contains comprehensive financial statements (income statement, cash flow, balance sheet data), management commentary, and operational updates. It is not a mere announcement of a report (RPA) as it contains the actual financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. Q1 2022
2022-04-27 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive quarterly report for Alligator Bioscience AB covering the period of January to March 2022. It includes detailed financial statements (Net sales, Operating profit/loss, Cash flow, etc.), management commentary, operational updates, and performance measures. It is not a short announcement or a certification, but a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.